Trump tariffs: these two European healthcare stocks face the highest US revenue exposure
President Trump has announced sweeping tariffs on several countries. Novo Nordisk and Smith & Nephew may be the most at risk ...
'I'm a doctor - I get asked these 7 questions about Mounjaro most often'
Here's everything you need to know about the new weight loss medication being rolled out by the NHS to treat obesity.
Artisan Global Opportunities Fund Trimmed its Position in Novo Nordisk A/S (NVO)
Artisan Partners, an investment management company, released its “Artisan Global Opportunities Fund” fourth quarter 2024 ...
PharmExec3h
The Vitamin Shoppe Launches GLP-1 Inspired Line of Supplements
The line-up consists of supplements to meet the health needs to patients taking GLP-1 medications for weight loss.
Ozempic, other semaglutides linked to hair loss: Here's what to know
Popular medications for obesity and diabetes have been linked to an increased risk of hair loss, particularly for women. Researchers and doctors weigh in.
Hims & Hers stock slipped as investors were left unimpressed with its new weight-loss drug options
Hims & Hers (HIMS) stock slid Wednesday, a day after the company announced new weight-loss drug offerings — an update that ...
‘Too Hot to Handle,’ Analyst Warning on Hims & Hers Health Stock (HIMS)
Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.
Pharmaceutical Commerce22h
Hims & Hers Begins Selling Zepbound
The telehealth company is offering Lilly’s branded form of tirzepatide—approved for weight loss—on its site for $1,899 a ...
Cryptopolitan23h
Trump’s tariffs are affecting unlikely industries, targeting America’s cosmetic and weight loss markets
President Donald Trump is expected to announce sweeping tariffs on “all countries" affecting many industries, the likes of ...